Journal
MICROBIOLOGY AND IMMUNOLOGY
Volume 58, Issue 4, Pages 219-226Publisher
WILEY-BLACKWELL
DOI: 10.1111/1348-0421.12140
Keywords
dengue; domain III; vaccine; virus
Categories
Funding
- Cuban Program for Dengue Vaccine Development
Ask authors/readers for more resources
A dengue vaccine must induce protective immunity against the four serotypes of the virus. Our group has developed chimeric proteins consisting of the protein P64k from Neisseria meningitidis and the domain III from the four viral envelope proteins. In this study, the immunogenicity of a tetravalent vaccine formulation using aluminum hydroxide as adjuvant was evaluated in mice. After three doses, neutralizing antibody titers were detected against the four viral serotypes, the lowest seroconversion rate being against dengue virus serotype 4. One month after the last dose, immunized animals were challenged with infective virus, and partial but statistically significant protection was found to have been achieved. Based on these results, further studies in mice and non-human primates using this tetravalent formulation in a prime-boost strategy with attenuated viruses are strongly recommended.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available